China Shineway Pharmaceutical Group Limited (2877.HK)
HKD 9.43
(-1.26%)
HKD 9.43
(-1.26%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.41 Billion CNY | 14.1% |
| 2022 | 2.11 Billion CNY | 18.22% |
| 2021 | 1.79 Billion CNY | 4.93% |
| 2020 | 1.7 Billion CNY | 17.4% |
| 2019 | 1.45 Billion CNY | 8.6% |
| 2018 | 1.34 Billion CNY | 71.66% |
| 2017 | 780.81 Million CNY | 12.86% |
| 2016 | 691.81 Million CNY | 4.65% |
| 2015 | 661.1 Million CNY | -9.08% |
| 2014 | 727.1 Million CNY | 3.74% |
| 2013 | 700.88 Million CNY | 4.92% |
| 2012 | 668.04 Million CNY | 89.47% |
| 2011 | 352.58 Million CNY | -28.22% |
| 2010 | 491.17 Million CNY | 44.37% |
| 2009 | 340.22 Million CNY | -27.74% |
| 2008 | 470.8 Million CNY | 27.47% |
| 2007 | 369.33 Million CNY | 46.81% |
| 2006 | 251.56 Million CNY | 8.26% |
| 2005 | 232.36 Million CNY | 35.39% |
| 2004 | 171.62 Million CNY | 63.82% |
| 2003 | 104.76 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q4 | 1.06 Billion CNY | 0.0% |
| 2023 Q2 | 1.18 Billion CNY | 0.0% |
| 2023 FY | 2.41 Billion CNY | 14.1% |
| 2022 Q4 | 1.15 Billion CNY | 0.0% |
| 2022 Q2 | 969.58 Million CNY | 0.0% |
| 2022 FY | 2.11 Billion CNY | 18.22% |
| 2021 Q4 | 976.71 Million CNY | 0.0% |
| 2021 FY | 1.79 Billion CNY | 4.93% |
| 2021 Q2 | 816.4 Million CNY | 0.0% |
| 2020 FY | 1.7 Billion CNY | 17.4% |
| 2020 Q2 | 631.47 Million CNY | 0.0% |
| 2020 Q4 | 1.07 Billion CNY | 0.0% |
| 2019 Q2 | 672.88 Million CNY | 0.0% |
| 2019 Q4 | 782.72 Million CNY | 0.0% |
| 2019 FY | 1.45 Billion CNY | 8.6% |
| 2018 FY | 1.34 Billion CNY | 71.66% |
| 2018 Q4 | 658.16 Million CNY | 0.0% |
| 2018 Q2 | 682.19 Million CNY | 0.0% |
| 2017 Q4 | 485.53 Million CNY | 0.0% |
| 2017 FY | 780.81 Million CNY | 12.86% |
| 2017 Q2 | 295.27 Million CNY | 0.0% |
| 2016 Q2 | 325.85 Million CNY | 0.0% |
| 2016 Q4 | 365.96 Million CNY | 0.0% |
| 2016 FY | 691.81 Million CNY | 4.65% |
| 2015 FY | 661.1 Million CNY | -9.08% |
| 2015 Q2 | 308.93 Million CNY | 0.0% |
| 2015 Q4 | 352.16 Million CNY | 0.0% |
| 2014 Q4 | 428.93 Million CNY | 0.0% |
| 2014 Q2 | 298.17 Million CNY | 0.0% |
| 2014 FY | 727.1 Million CNY | 3.74% |
| 2013 Q4 | 412.85 Million CNY | 0.0% |
| 2013 Q2 | 288.03 Million CNY | 0.0% |
| 2013 FY | 700.88 Million CNY | 4.92% |
| 2012 Q4 | 175.11 Million CNY | 4.85% |
| 2012 Q3 | 167.01 Million CNY | 0.0% |
| 2012 Q2 | 167.01 Million CNY | 0.0% |
| 2012 Q1 | 167.01 Million CNY | 0.0% |
| 2012 FY | 668.04 Million CNY | 89.47% |
| 2011 Q1 | -47.36 Million CNY | 0.0% |
| 2011 Q2 | -47.36 Million CNY | 0.0% |
| 2011 Q3 | -47.36 Million CNY | 0.0% |
| 2011 Q4 | 167.01 Million CNY | 452.63% |
| 2011 FY | 352.58 Million CNY | -28.22% |
| 2010 Q4 | -47.36 Million CNY | -144.46% |
| 2010 Q1 | -19.37 Million CNY | 0.0% |
| 2010 FY | 491.17 Million CNY | 44.37% |
| 2010 Q3 | -19.37 Million CNY | 0.0% |
| 2010 Q2 | -19.37 Million CNY | 0.0% |
| 2009 Q3 | -45.61 Million CNY | 0.0% |
| 2009 FY | 340.22 Million CNY | -27.74% |
| 2009 Q1 | -45.61 Million CNY | 0.0% |
| 2009 Q4 | -19.37 Million CNY | 57.52% |
| 2009 Q2 | -45.61 Million CNY | 0.0% |
| 2008 Q4 | -45.61 Million CNY | -292.93% |
| 2008 FY | 470.8 Million CNY | 27.47% |
| 2008 Q1 | 23.64 Million CNY | 0.0% |
| 2008 Q2 | 23.64 Million CNY | 0.0% |
| 2008 Q3 | 23.64 Million CNY | 0.0% |
| 2007 Q1 | 7.58 Million CNY | 0.0% |
| 2007 FY | 369.33 Million CNY | 46.81% |
| 2007 Q4 | 23.64 Million CNY | 211.79% |
| 2007 Q3 | 7.58 Million CNY | 0.0% |
| 2007 Q2 | 7.58 Million CNY | 0.0% |
| 2006 Q1 | 45.96 Million CNY | 0.0% |
| 2006 FY | 251.56 Million CNY | 8.26% |
| 2006 Q2 | 45.96 Million CNY | 0.0% |
| 2006 Q3 | 45.96 Million CNY | 0.0% |
| 2006 Q4 | 7.58 Million CNY | -83.5% |
| 2005 Q3 | 40.22 Million CNY | 0.0% |
| 2005 Q2 | 40.22 Million CNY | 0.0% |
| 2005 FY | 232.36 Million CNY | 35.39% |
| 2005 Q4 | 45.96 Million CNY | 14.26% |
| 2005 Q1 | 40.22 Million CNY | 0.0% |
| 2004 Q4 | 40.22 Million CNY | 38.11% |
| 2004 Q1 | 29.12 Million CNY | 0.0% |
| 2004 Q2 | 29.12 Million CNY | 0.0% |
| 2004 Q3 | 29.12 Million CNY | 0.0% |
| 2004 FY | 171.62 Million CNY | 63.82% |
| 2003 FY | 104.76 Million CNY | 0.0% |
| 2003 Q1 | 17.5 Million CNY | 0.0% |
| 2003 Q4 | 29.12 Million CNY | 66.36% |
| 2003 Q3 | 17.5 Million CNY | 0.0% |
| 2003 Q2 | 17.5 Million CNY | 0.0% |
| 2002 Q4 | 17.5 Million CNY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 24.42 Million HKD | -9802.489% |
| Grand Pharmaceutical Group Limited | 3.86 Billion HKD | 37.353% |
| Extrawell Pharmaceutical Holdings Limited | 35.52 Million HKD | -6707.735% |
| Wai Yuen Tong Medicine Holdings Limited | 353.93 Million HKD | -583.345% |
| Qianhai Health Holdings Limited | 17.1 Million HKD | -14042.112% |
| Lee's Pharmaceutical Holdings Limited | 590.99 Million HKD | -309.241% |
| Essex Bio-Technology Limited | 1.22 Billion HKD | -96.799% |
| Tongfang Kontafarma Holdings Limited | 503.46 Million HKD | -380.39% |
| PuraPharm Corporation Limited | 216.62 Million HKD | -1016.464% |
| SSY Group Limited | 1.98 Billion HKD | -22.105% |
| JBM (Healthcare) Limited | 163.87 Million HKD | -1375.862% |
| Jacobson Pharma Corporation Limited | 287.34 Million HKD | -741.689% |
| China Resources Pharmaceutical Group Limited | 29.35 Billion HKD | 91.761% |